Page last updated: 2024-08-25

bendamustine hydrochloride and Granuloma, Hodgkin

bendamustine hydrochloride has been researched along with Granuloma, Hodgkin in 57 studies

Research

Studies (57)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.75)18.7374
1990's1 (1.75)18.2507
2000's2 (3.51)29.6817
2010's32 (56.14)24.3611
2020's21 (36.84)2.80

Authors

AuthorsStudies
Akay, OM; Altuntaş, F; Başcı, S; Büyükkurt, N; Dal, MS; Ferhanoğlu, B; Güneş, AK; Hindilerden, F; Kızıl Çakar, M; Korkmaz, S; Mehtap, Ö; Nalçacı, M; Özet, G; Ulaş, T; Uncu Ulu, B; Yanardağ Açık, D; Yiğenoğlu, TN; Yönal Hindilerden, İ1
Absalon, MJ; Castellino, SM; Forlenza, CJ; Franklin, A; Gulati, N; Keller, FG; Mauguen, A; Shukla, N1
Bolis, S; Botto, B; Cantonetti, M; Fabbri, A; Falchi, L; Galieni, P; Gini, G; Liberati, AM; Moretti, M; Pavone, V; Puccini, B; Pulsoni, A; Renzi, D; Rigacci, L1
Buffardi, S; De Vito, R; Del Bufalo, F; Di Matteo, A; Di Ruscio, V; Locatelli, F; Mariggiò, E; Paganelli, V; Pagliara, D; Parasole, R; Petruzziello, F; Stocchi, F; Strocchio, L; Vinti, L1
Afanasyev, B; Beynarovich, A; Borzenkova, E; Kondakova, E; Kozlov, A; Kulagin, A; Lepik, K; Mikhailova, N; Moiseev, I; Pirogova, O; Stelmakh, L; Volkov, N; Zalyalov, Y; Zubarovskaya, L1
Agbetiafa, K; Amorim, S; Aubrais, R; Banos, A; Bellal, M; Besson, C; Bijou, F; Bonnet, C; Bouabdallah, K; Brice, P; Chartier, L; Chauchet, A; Cluzeau, T; Daguindau, N; Damaj, G; Delapierre, B; Durot, E; Fouillet, L; Gaulard, P; Herbaux, C; Laribi, K; Le Calloch, R; Parrens, MC; Schiano, JM; Sibon, D; Tournilhac, O1
Amoroso, L; Beishuizen, A; Buffardi, S; Cole, PD; Cooper, S; Daw, S; Drachtman, RA; Francis, S; Harker-Murray, P; Hoppe, BS; Kelly, KM; Leblanc, T; Leger, KJ; Lisano, J; Mascarin, M; Mauz-Körholz, C; Michel, G; Rigaud, C; Sacchi, M1
Al Batran, M; Al Darweesh, M; Al Garni, A; Al Hashmi, H; Al Naim, A; Al Zayer, M; Kaloyannidis, P; Kanfar, S1
Amengual, JE; Tolu, SS1
Amin, NH; El-Saadi, MT; Mohamed, NR; Sharkawi, MMZ1
Crews, KR; Flerlage, JE; Niloy, KK; Panetta, JC; Purvis, KN; Swanson, HD; Zhou, Y1
Kuittinen, O; Kuitunen, H; Kuusisto, MEL; Paloneva, T; Prusila, REI; Rämet, M; Teppo, HR; Väyrynen, JP; Vuolio, T1
Beishuizen, A; Boes, M; Diez, C; Greve, P; Hagleitner, M; Loeffen, J; Meyer-Wentrup, F; Peperzak, V; Veening, M1
Argnani, L; Botto, B; Broccoli, A; Corradini, P; Fanti, S; Pinto, A; Re, A; Stefoni, V; Vitolo, U; Zinzani, PL1
Egle, A; Greil, R; Jäger, U; Keil, F; Lehner, B; Magnes, T; Melchardt, T; Panny, M; Sillaber, C; Simonitsch-Klupp, I; Skrabs, C; Staber, P; Wagner, SM1
Anastasia, A; Annechini, G; Bonfichi, M; Carlo-Stella, C; Castagna, L; Di Renzo, N; Giordano, L; Gotti, M; Liberati, AM; Luminari, S; Mazza, R; Merli, F; Peli, A; Pulsoni, A; Re, A; Ricci, F; Santoro, A; Zanni, M; Zilioli, VR1
Advani, R; Agura, E; Ansell, SM; Behler, C; Bociek, RG; Caimi, P; Cheung, E; Crosswell, HE; Forero-Torres, A; Islas-Ohlmayer, M; Josephson, N; LaCasce, AS; Matous, J; O'Connor, OA; Sawas, A; Vose, J; Wang, Y2
Bonanno, V; Caruso, AL; Cascavilla, N; Chiarenza, A; Consoli, U; Crescimanno, A; De Santis, G; Di Raimondo, F; Greco, A; Guarini, A; Iannitto, E; Li Gioi, F; Mannina, D; Mantuano, S; Minoia, C; Musso, M; Pavone, E; Pirosa, MC; Porretto, F; Ricciuti, G; Romano, A; Salerno, M; Scalone, R; Scalzulli, PR; Tarantini, G1
Beaven, AW; Brenner, MK; Buchanan, FB; Cheng, CJ; Dittus, C; Dotti, G; Eldridge, PW; Gee, AP; Grilley, BJ; Grover, NS; Heslop, HE; Ivanova, A; Lulla, PD; McKay, KL; Mehta, B; Morrison, K; Park, SI; Ramos, CA; Rooney, CM; Savoldo, B; Serody, JS; Shea, TC; Wang, T; Wu, MF1
Cheng, B; Connors, JM; Crump, M; Deng, C; Kuruvilla, J; Lue, JK; Ma, H; Marchi, E; Montanari, F; O'Connor, OA; Savage, KJ; Sawas, A; Villa, D1
Földeák, D; Gopcsa, L; Illés, Á; Miltényi, Z; Pinczés, LI; Piukovics, K; Szabó, R; Szomor, Á1
Ardeshna, KM; Carpenter, B; Daw, S; Grandage, V; Hough, R; Humphries, P; Lambert, J; McMillan, A; Menezes, L; O'Neill, AT; Shah, R; Townsend, W; Virchis, A; Von Both, K1
Bazarbachi, A; El Cheikh, J; Fares, E; Haffar, B; Ibrahim, A; Jisr, T; Kharfan-Dabaja, MA; Mahfouz, R; Massoud, R; Mougharbel, A; Youssef, A1
Alenxandrova, K; Arfi-Rouche, J; Bourhis, JH; Castilla-Llorente, C; Danu, A; Ghez, D; Khalife-Saleh, N; Koscielny, S; Lapierre, V; Lazarovici, J; Legoupil, C; Michot, JM; Pilorge, S; Ribrag, V; Saleh, K1
Chiappella, A; Vitolo, U1
Haapasaari, KM; Karjalainen-Lindsberg, ML; Kuittinen, O; Marin, K; Pollari, M; Prusila, REI; Soini, Y; Turpeenniemi-Hujanen, T; Vornanen, M1
Gordon, LI1
Brice, P; Casasnovas, O; Clément, L; Ferlay, C; Gabarre, J; Ghesquières, H; Gyan, E; Malphettes, M; Morschhauser, F; Stamatoullas, A1
Argnani, L; Broccoli, A; Celli, M; Derenzini, E; Pellegrini, C; Zinzani, PL1
Moskowitz, A1
Anastasia, A; Brusamolino, E; Carlo-Stella, C; Corradini, P; Giordano, L; Hohaus, S; Luminari, S; Pregno, P; Pulsoni, A; Rusconi, C; Salvi, F; Santoro, A; Viviani, S1
Elsoueidi, R; Mourad, H; Mulat, A1
Bramanti, S; Bruno-Ventre, M; Castagna, L; Ciceri, F; Corti, C; Crocchiolo, R; Gandolfi, S; Marktel, S; Peccatori, J; Sala, E; Santoro, A; Sarina, B1
Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL1
Argnani, L; Broccoli, A; Cascavilla, N; Corradini, P; Hohaus, S; Merli, F; Motta, G; Tani, M; Vitolo, U; Viviani, S; Zinzani, PL1
Illés, Á; Jóna, Á; Miltényi, Z; Simon, Z; Udvardy, M1
Anderlini, P; Cheah, CY; Chihara, D; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Horowitz, S; Nastoupil, LJ; Neelapu, SS; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, JE; Samaniego, F; Sevin, A; Turturro, F; Wang, M; Westin, JR; Zhou, S1
Zahid, MF1
Anastasia, A; Annechini, G; Bonfichi, M; Carlo-Stella, C; Castagna, L; Di Renzo, N; Giordano, L; Gotti, M; Liberati, AM; Luminari, S; Mazza, R; Merli, F; Peli, A; Pulsoni, A; Re, A; Salvi, F; Santoro, A; Zilioli, VR1
Venkatesan, P1
Gibb, A; Howell, M; Linton, K; Radford, J1
Amengual, JE; Connors, JM; Deng, C; Kalac, M; Kuruvilla, J; Lichtenstein, E; Lue, JK; Mapara, MY; O'Connor, OA; Rojas, C; Sawas, A; Turenne, I1
Dougherty, DW; Friedberg, JW1
Bauer, K; Brillant, C; Engert, A; Herbst, C; Kluge, S; Monsef, I; Skoetz, N1
Annechini, G; Breccia, M; Cavalieri, E; D'Elia, GM; Danieli, R; De Angelis, F; Panfilio, S; Pulsoni, A1
Caballero, MD; Capria, S; Cuberli, F; Falcioni, S; Ferrara, F; Galieni, P; Gaudio, F; Gherlinzoni, F; Giardini, C; Gobbi, M; Isidori, A; Malerba, L; Meloni, G; Ocio, EM; Rocchi, M; Santoro, A; Sarina, B; Specchia, G; Stefani, PM; Visani, G1
Barna, S; Illés, Á; Magyari, F; Simon, Z; Udvardy, M; Váróczy, L1
Moskowitz, AJ1
Casini, M; Cavattoni, IM; Cortelazzo, S; Deola, S; Farsad, M; Mian, M; Pescosta, N1
Amore, A; Angrilli, F; Arcamone, M; Califano, C; Corazzelli, G; Cox, MC; D'Arco, A; De Filippi, R; Falorio, S; Ferrara, F; Guarini, A; Iannitto, E; Musto, P; Pinto, A; Stelitano, C; Storti, S1
Gerecitano, J; Graustein, T; Hamlin, PA; Horwitz, SM; Matasar, MJ; Moskowitz, AJ; Moskowitz, CH; Noy, A; Palomba, ML; Perales, MA; Portlock, CS; Straus, DJ; Zelenetz, AD1
Cheson, BD; Diehl, V1
Borchmann, P; Diehl, V; Engert, A; Schnell, R1
Balfour, JA; Goa, KL1
Anger, G; Herold, M; Höche, D; Kästner, R1

Reviews

4 review(s) available for bendamustine hydrochloride and Granuloma, Hodgkin

ArticleYear
Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?
    Current hematologic malignancy reports, 2010, Volume: 5, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Lenalidomide; Nitrogen Mustard Compounds; Rituximab; Thalidomide; Vinblastine; Vinorelbine

2010
Novel agents in Hodgkin lymphoma.
    Current oncology reports, 2012, Volume: 14, Issue:5

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Brentuximab Vedotin; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Nitrogen Mustard Compounds; Protein Kinase Inhibitors; Sirolimus; Thalidomide

2012
New drugs in the treatment of Hodgkin's disease.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9 Suppl 5

    Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bendamustine Hydrochloride; Deoxycytidine; Drug Therapy; Gemcitabine; Hodgkin Disease; Humans; Idarubicin; Immunotoxins; Nitrogen Mustard Compounds; Vinblastine; Vinorelbine

1998
Bendamustine.
    Drugs, 2001, Volume: 61, Issue:5

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Breast Neoplasms; Female; Half-Life; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Metabolic Clearance Rate; Nitrogen Mustard Compounds

2001

Trials

11 trial(s) available for bendamustine hydrochloride and Granuloma, Hodgkin

ArticleYear
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
    Blood, 2023, 04-27, Volume: 141, Issue:17

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Nivolumab; Treatment Outcome; Young Adult

2023
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.
    Blood cancer journal, 2019, 12-11, Volume: 9, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Combined Modality Therapy; Female; Hodgkin Disease; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Grading; Salvage Therapy; Tomography, X-Ray Computed; Treatment Outcome; Young Adult

2019
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
    Blood advances, 2020, 01-14, Volume: 4, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Deoxycytidine; Disease-Free Survival; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Recurrence; Transplantation, Autologous

2020
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 11-10, Volume: 38, Issue:32

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality Therapy; Cyclophosphamide; Epitopes; Female; Hodgkin Disease; Humans; Immunotherapy, Adoptive; Ki-1 Antigen; Lymphocyte Depletion; Male; Middle Aged; Stem Cell Transplantation; Vidarabine; Young Adult

2020
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/I
    Leukemia & lymphoma, 2020, Volume: 61, Issue:12

    Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Progression-Free Survival

2020
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    Blood, 2018, 07-05, Volume: 132, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Disease-Free Survival; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Recurrence; Salvage Therapy; Survival Rate; Time Factors

2018
Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.
    Clinical advances in hematology & oncology : H&O, 2016, Volume: 14, Issue:2 Suppl 1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Cohort Studies; Dacarbazine; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local

2016
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 09-20, Volume: 34, Issue:27

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Transplantation, Autologous; Vinblastine; Vinorelbine; Young Adult

2016
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
    Blood, 2011, Sep-22, Volume: 118, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous

2011
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-01, Volume: 31, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Treatment Outcome

2013
[Preliminary results of cyclically alternating chemotherapy (CVPP/DBVCy) in advanced Hodgkin's disease].
    Medizinische Klinik (Munich, Germany : 1983), 1987, May-08, Volume: 82, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bleomycin; Clinical Trials as Topic; Daunorubicin; Drug Administration Schedule; Female; Hodgkin Disease; Humans; Lomustine; Male; Middle Aged; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Random Allocation; Vinblastine; Vincristine

1987

Other Studies

42 other study(ies) available for bendamustine hydrochloride and Granuloma, Hodgkin

ArticleYear
Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
    Journal of chemotherapy (Florence, Italy), 2022, Volume: 34, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome

2022
Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma.
    Blood advances, 2021, 12-28, Volume: 5, Issue:24

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Retrospective Studies; Treatment Outcome; Young Adult

2021
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
    Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Transplantation, Autologous; Treatment Outcome

2022
Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.
    Pediatric blood & cancer, 2022, Volume: 69, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Young Adult

2022
Favorable outcomes of allogeneic hematopoietic stem cell transplantation with fludarabine-bendamustine conditioning and posttransplantation cyclophosphamide in classical Hodgkin lymphoma.
    International journal of hematology, 2022, Volume: 116, Issue:3

    Topics: Adult; Bendamustine Hydrochloride; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2022
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
    Blood advances, 2023, 10-10, Volume: 7, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Chronic Disease; Hodgkin Disease; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome

2023
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
    Leukemia & lymphoma, 2023, Volume: 64, Issue:3

    Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome

2023
Queen's gambit: response-adapted win in CAYA with cHL.
    Blood, 2023, 04-27, Volume: 141, Issue:17

    Topics: Adolescent; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Nivolumab; Young Adult

2023
Determination of Bendamustine, Gemcitabine and Vinorelbine (BEGEV) regimen in spiked human plasma using multivariate model update chemometric methods.
    Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2023, Oct-15, Volume: 299

    Topics: Bendamustine Hydrochloride; Chemometrics; Chromatography, Liquid; Gemcitabine; Hodgkin Disease; Humans; Tandem Mass Spectrometry; Vinorelbine

2023
Pharmacokinetics and safety of bendamustine in the BEABOVP regimen for the treatment of pediatric patients with Hodgkin lymphoma.
    Cancer chemotherapy and pharmacology, 2023, Volume: 92, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Child; Doxorubicin; Hodgkin Disease; Humans; Mechlorethamine; Neoplasm Recurrence, Local

2023
R-bendamustine in the treatment of nodular lymphocyte predominant Hodgkin lymphoma-An extended follow-up.
    British journal of haematology, 2023, Volume: 202, Issue:4

    Topics: Bendamustine Hydrochloride; Follow-Up Studies; Hodgkin Disease; Humans; Lymph Nodes; Lymphocytes

2023
Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Nivolumab; Treatment Outcome

2023
Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    European journal of haematology, 2020, Volume: 104, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Combined Modality Therapy; Female; Hodgkin Disease; Humans; Induction Chemotherapy; Ki-1 Antigen; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prognosis; Treatment Outcome; Young Adult

2020
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.
    British journal of haematology, 2020, Volume: 189, Issue:3

    Topics: Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; Brentuximab Vedotin; Female; Hodgkin Disease; Humans; Male; Salvage Therapy; Survival Analysis; Time Factors; Treatment Outcome

2020
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
    European journal of haematology, 2020, Volume: 104, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Recurrence; Treatment Outcome; Young Adult

2020
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Annals of hematology, 2020, Volume: 99, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Neutropenia; Peripheral Nervous System Diseases; Positron-Emission Tomography; Progression-Free Survival; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult

2020
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.
    British journal of haematology, 2021, Volume: 192, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Female; Hodgkin Disease; Humans; Male; Neoplasm Recurrence, Local; Treatment Outcome; Young Adult

2021
Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:11

    Topics: Adolescent; Adult; Bendamustine Hydrochloride; Brentuximab Vedotin; Combined Modality Therapy; Hodgkin Disease; Humans; Immunoconjugates; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Positron Emission Tomography Computed Tomography; Transplantation, Homologous; Treatment Outcome; Young Adult

2017
A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.
    Leukemia & lymphoma, 2018, Volume: 59, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Carmustine; Case-Control Studies; Cytarabine; Diarrhea; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2018
Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era.
    The Lancet. Oncology, 2018, Volume: 19, Issue:2

    Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Immunoconjugates; Salvage Therapy

2018
R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma.
    Acta oncologica (Stockholm, Sweden), 2018, Volume: 57, Issue:9

    Topics: Adult; Bendamustine Hydrochloride; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Middle Aged; Neoadjuvant Therapy; Recurrence; Retrospective Studies; Young Adult

2018
Getting to transplant in Hodgkin lymphoma: BVB.
    Blood, 2018, 07-05, Volume: 132, Issue:1

    Topics: Bendamustine Hydrochloride; Brentuximab Vedotin; Child; Hodgkin Disease; Humans; Immunoconjugates; Salvage Therapy

2018
Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Compassionate Use Trials; Female; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Nitrogen Mustard Compounds; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult

2013
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
    British journal of haematology, 2013, Volume: 163, Issue:5

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bleomycin; Brentuximab Vedotin; Combined Modality Therapy; Dacarbazine; Doxorubicin; Drug Resistance, Neoplasm; Hodgkin Disease; Humans; Immunoconjugates; Male; Nitrogen Mustard Compounds; Positron-Emission Tomography; Radiotherapy, Adjuvant; Recurrence; Salvage Therapy; Vinblastine; Young Adult

2013
Bendamustine: a bridge to longer term solutions in heavily treated Hodgkin lymphoma.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Female; Hodgkin Disease; Humans; Male; Nitrogen Mustard Compounds

2013
Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi.
    British journal of haematology, 2014, Volume: 166, Issue:1

    Topics: Adult; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitrogen Mustard Compounds; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Failure; Treatment Outcome; Young Adult

2014
Bendamustine treatment in a heavily pretreated Hodgkin lymphoma patient.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Hodgkin Disease; Humans; Male; Middle Aged; Prognosis; Remission Induction

2014
Bendamustine combined with donor lymphocytes infusion in Hodgkin's lymphoma relapsing after allogeneic hematopoietic stem cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocytes; Neoplasm Recurrence, Local; Nitrogen Mustard Compounds; Transplantation Conditioning

2014
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
    Hematological oncology, 2016, Volume: 34, Issue:1

    Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult

2016
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Brentuximab Vedotin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Failure; Young Adult

2015
[Novel treatment options in relapsed and refracter Hodgkin lymphomas].
    Orvosi hetilap, 2015, Nov-08, Volume: 156, Issue:45

    Topics: Adult; Antineoplastic Agents; B7-H1 Antigen; Bendamustine Hydrochloride; Brentuximab Vedotin; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hungary; Immunoconjugates; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Sclerosis; Survival Analysis; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome

2015
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Brentuximab Vedotin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Treatment Outcome

2016
Treating the Hodgkin's Lymphoma Variant of Richter's Transformation.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2016, Volume: 26, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell

2016
Bendamustine combined regimen for Hodgkin's lymphoma.
    The Lancet. Oncology, 2016, Volume: 17, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Hodgkin Disease; Humans; Remission Induction; Treatment Outcome

2016
Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    British journal of haematology, 2017, Volume: 179, Issue:5

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Recurrence; Retreatment; Transplantation, Homologous; Treatment Outcome

2017
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
    British journal of haematology, 2018, Volume: 180, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Treatment Outcome; Young Adult

2018
Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma.
    Journal of the National Cancer Institute, 2010, Jun-16, Volume: 102, Issue:12

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bendamustine Hydrochloride; Bleomycin; Chlorambucil; Controlled Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Exercise; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multicenter Studies as Topic; Myelodysplastic Syndromes; Nitrogen Mustard Compounds; Prednisone; Procarbazine; Quality of Life; Randomized Controlled Trials as Topic; Vinblastine; Vincristine

2010
Efficacy of bendamustine as salvage treatment in an heavily pre-treated Hodgkin lymphoma.
    Leukemia research, 2010, Volume: 34, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Hodgkin Disease; Humans; Male; Nitrogen Mustard Compounds; Treatment Outcome

2010
Successful administration of rituximab-bendamustine regimen in the relapse of Hodgkin lymphoma after autologous hemopoietic stem cell transplantation.
    Hematological oncology, 2012, Volume: 30, Issue:2

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Nitrogen Mustard Compounds; Recurrence; Rituximab; Salvage Therapy; Transplantation, Autologous

2012
Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
    Annals of hematology, 2013, Volume: 92, Issue:1

    Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bleomycin; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Deoxycytidine; Doxorubicin; Etoposide; Fatal Outcome; Female; Gemcitabine; Graft vs Host Disease; Hodgkin Disease; Humans; Ifosfamide; Male; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Procarbazine; Recurrence; Reoperation; Rituximab; Salvage Therapy; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine; Vinorelbine; Young Adult

2013
Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.
    British journal of haematology, 2013, Volume: 160, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle Checkpoints; Combined Modality Therapy; Disease-Free Survival; DNA Repair; Drug Evaluation; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Nitrogen Mustard Compounds; Off-Label Use; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Young Adult

2013
Bendamustine in the treatment of hematologic malignancies. Introduction.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Hematologic Neoplasms; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nitrogen Mustard Compounds

2002